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Botulinum neurotoxins (BoNTs) are known as the most potent bacterial toxins, which can
cause potentially deadly disease botulism. BoNT Serotype A (BoNT/A) is the most studied
serotype as it is responsible for most human botulism cases, and its formulations are
extensively utilized in clinics for therapeutic and cosmetic applications. BoNT/A has the
longest-lasting effect in neurons compared to other serotypes, and there has been high
interest in understanding how BoNT/A manages to escape protein degradation machinery
in neurons for months. Recent work demonstrated that an E3 ligase, HECTD2, leads to
efficient ubiquitination of the BoNT/A Light Chain (A/LC); however, the dominant activity of
a deubiquitinase (DUB), VCIP135, inhibits the degradation of the enzymatic component.
Another DUB, USP9X, was also identified as a potential indirect contributor to A/LC
degradation. In this study, we screened a focused ubiquitin-proteasome pathway inhibitor
library, including VCIP135 and USP9X inhibitors, and identified ten potential lead
compounds affecting BoNT/A mediated SNAP-25 cleavage in neurons in pre-
intoxication conditions. We then tested the dose-dependent effects of the compounds
and their potential toxic effects in cells. A subset of the lead compounds demonstrated
efficacy on the stability and ubiquitination of A/LC in cells. Three of the compounds,
WP1130 (degrasyn), PR-619, and Celastrol, further demonstrated efficacy against BoNT/
A holotoxin in an in vitro post-intoxication model. Excitingly, PR-619 and WP1130 are
known inhibitors of VCIP135 and USP9X, respectively. Modulation of BoNT turnover in
cells by small molecules can potentially lead to the development of effective
countermeasures against botulism.
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INTRODUCTION
Botulinum neurotoxins (BoNT) are the causative agents of
botulism disease, which can be lethal mainly due to
respiratory failure (Johnson, 2019). Their extreme toxicities
and ease of production led to the classification of BoNTs as
Category A bioterror agents, and BoNTs have been attempted for
use as biological weapons in the past (Arnon et al., 2001). On the
other hand, formulations of these toxins are extensively utilized in
clinics as FDA-approved therapeutics to treat various conditions
such as movement disorders as well as for cosmetic purposes
(Choudhury et al., 2021). BoNT intoxication primarily leads to
inhibition of the motor neuron-muscle connectivity by cleaving
specific SNARE proteins crucial for neuroexocytosis (Montal,
2010). After these toxins have gained entry into motor neurons,
there are no treatment options to inhibit their enzymatic activity
inside the cell (Lin et al., 2019). There are at least seven different
BoNT serotypes with an increasing number of subtypes and
chimeric toxins (Dong and Stenmark, 2021), of which
serotypes A, B, E, and F lead to human botulism (Maslanka,
2014). Among these, serotype A (BoNT/A) causes the most
human botulism cases, and it is the most utilized BoNT
serotype in clinical formulations (Choudhury et al., 2021).
This serotype has the most prolonged half-life in neurons
compared to other serotypes (Shoemaker and Oyler, 2013).
For example, both BoNT/A and another human botulism-
causing serotype, BoNT/E, target the same protein, SNAP-25,
in neurons; however, BoNT/E is destroyed naturally within a few
days to weeks while BoNT/A can be active for up to 6 months in
the neuronal cytosol (Shoemaker and Oyler, 2013).
Recent work elucidated the molecular mechanisms by which
BoNT/A Light Chain (A/LC) evades the ubiquitin-proteasome
pathway (UPP) in neurons (Tsai et al., 2017). More specifically,
A/LC is ubiquitinated by the E3 ligase, HECTD2, but it is
protected from proteasomal destruction by the dominant effect
of VCIP135/VCPIP1, a deubiquitinase (DUB) (Tsai et al., 2017).
Notably, previous work provided proof-of-concept that A/LC
turnover in cells can be modified by increasing its ubiquitination
via designer E3 ligases (Tsai et al., 2010) or by delivering fusion
proteins, including a single-chain antibody specific to A/LC fused
to an F-box domain recognized by an endogenous E3-ligase (Kuo
et al., 2011). However, to pave the road for drug development
studies, it is crucial to identify small molecules that can modulate
UPP to affect A/LC toxicity. There have been extensive drug
development efforts against BoNT/A, and although elegant work
from many groups has identified various compound classes as
BoNT/A inhibitors, none has graduated to clinical trials yet (Lin
et al., 2019). To the best of our knowledge, targeting UPP with
small molecules to modulate the persistence of A/LC has not been
explored. Although UPP is considered a highly challenging drug
target, there are already FDA-approved and many promising
clinical/preclinical stage compounds targeting different
components of UPP (Wu et al., 2020). For example,
proteasome inhibitors Bortezomib, Carfilzomib, Ixazomib, and
E3 modulators Thalidomide, Lenalidomide, and Pomalidomide
are FDA approved (Wu et al., 2020). In the UPP pathway, DUBs
are considered attractive drug targets with significant clinical
potential as it may be possible to develop selective DUB
modulators due to their diversity (about 100 DUBs in
humans) (Basar et al., 2021), and well-defined catalytic clefts
(Clague et al., 2019). Indeed, selective DUBmodulators, although
a few, have been developed (Harrigan et al., 2018; Clancy et al.,
2021).
In this work, we focused on identifying small molecules to
potentially affect ubiquitination and/or deubiquitination of the
A/LC to modulate the A/LC activity in cells. Previous work
demonstrated that, in addition to VCIP135/VCPIP1, another
DUB, USP9X, potentially indirectly affects the stability of
A/LC in cells (Tsai et al., 2017), suggesting that there may be
other crucial, indirect players in this process. Therefore, we
sought to utilize a more general approach rather than focusing
on just the known UPP factors for A/LC turnover and screened a
focused UPP inhibitor library including VCIP135 and USP9X
inhibitors to identify compounds modulating BoNT/A toxicity in
cells. Our initial screen utilizing mouse embryonic stem cell-
derived motor neurons identified ten potential lead compounds
affecting BoNT/A holotoxin mediated SNAP-25 cleavage in
neurons in a pre-intoxication experimental model. Then, we
examined the dose-dependent effects of the selected
compounds and tested their effects on cell viability. We also
explored the effects of the lead compounds on the stability and the
ubiquitination of the A/LC in cells. Among the identified small
molecules, PR-619 and WP1130 (degrasyn) appear to be highly
crucial as they are the known inhibitors of VCIP135 and USP9X,
respectively, which have been identified as DUBs affecting the
half-life of A/LC (Tsai et al., 2017). Importantly, PR-619,
WP1130, and Celastrol also exhibited efficacy against BoNT/A
holotoxin in post-intoxication experimental conditions.
MATERIALS AND METHODS
Compound Library
The ubiquitin-proteasome pathway inhibitor library was
purchased from LifeSensors (#SI9032), which contained 32
UPP inhibitors. The library comprises small molecules
targeting many components in UPP (i.e., E1, E3, proteasome),
including DUB inhibitors. Compound stock concentrations in
the library were 10 mM, dissolved in dimethyl sulfoxide (DMSO).
All of the compounds in the purchased library were tested in
Figure 1.
Differentiation of Mouse Embryonic Stem
Cells Into Motor Neurons
Directed differentiation of mouse ES (HBG3) cells towards motor
neurons were based on our previously established and
characterized protocols (Kiris et al., 2011; Kota et al., 2014).
Briefly, HBG3 ES cells were co-cultured with mitomycin-
inactivated mouse embryonic fibroblast (mitoMEF), using
mouse ES medium consisting of DMEM supplemented with
15% fetal bovine serum (FBS), 1,000 Unit/ml Leukemia
Inhibitory Factor (LIF), β-mercaptoethanol (final
concentration 0.1 mM), 1% Penicillin-Streptomycin, 1%
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Glutamax, and 1% Non-essential amino acids. For motor neuron
differentiation, the mouse ES cells were separated from
mitoMEFs via enzymatic methods, and embryoid bodies (EBs)
were formed (Day 0) using the differentiation medium, which
was composed of 1:1 Advanced DMEM-F12 and Neurobasal
medium supplemented with 1% Penicillin-Streptomycin, 1%
Glutamax, β-mercaptoethanol (final concentration 0.1 mM),
and 10% Knockout Serum Replacement, using low-attachment
dishes. On differentiation day 1, the EBs were collected and
cultured in a fresh differentiation medium for 24 h. For the
induction of neuralization, the EBs were then treated (Day 2)
with Retinoic Acid (1 μM, Sigma) for 24 h. On days 3 and 4, Hh-
Ag1.5 (Cellagentech) (1 µM final concentration) was utilized to
induce motor neuron specification. On day 5, EBs were
transferred to new plates with fresh differentiation medium,
supplemented with 2% B-27 serum-free supplement
(Invitrogen), brain-derived neurotrophic factor (10 ng/ml,
Chemicon), glial cell-derived neurotrophic factor (100 ng/ml, R&D
Systems), ciliary-derived neurotrophic factors (10 ng/ml, Chemicon),
and Neurotrophin3 (10 ng/ml, Chemicon). On day 7, EBs were
dissociated using accutase, counted, and plated to matrigel (BD
Biosciences) coated dishes for 3 days of neurite elongation. Unless
otherwise stated, all reagents were purchased from Thermo Fisher
Scientific.
BoNT/A Intoxication, Compound
Treatments, and Western Blotting
For BoNT/A holotoxin (Metabiologics) experiments with pre-
intoxication conditions (Figures 1, 3), mouse ES cell-derived
motor neurons were cultured in 24-well plate formats and pre-
treated with compounds and cultured for 30 min at 37°C with 5%
CO2 prior to intoxication, similar to previous studies (Kiris et al.,
2015a; Kiris et al., 2015b). Neurons were then intoxicated with the
holotoxin for 4 h in a humidified incubator with 5% CO2 at 37°C.
For the post intoxication conditions in Figure 7; neurons were
first intoxicated with indicated amounts of BoNT/A holotoxin,
cultured for 30 min, and then the compounds were supplied to
the intoxicated cultures. Total intoxication time was kept as
4 h. At the end of the holotoxin experiments in both pre- and
FIGURE 1 | The initial screen of the small molecule UPP inhibitor library for BoNT inhibition in mouse ES-derived motor neurons in pre-intoxication conditions.
Mouse ES-derived motor neurons were treated with small molecules (20 µM) for 30 min and then intoxicated with BoNT/A holotoxin (500 pM) for 4 h. Western blotting
was utilized to calculate percent full-length (intact) SNAP-25 cleavage in each condition. Toosendanin, a known BoNT inhibitor, was used as a positive control. β-Actin
was used as a loading control. Data are presented as means ± SEM calculated from three independent experiments and compared by Student’s t-test to
DMSO+500pM BoNT/A condition. +++, ++, + Value significant at 99.9%, 99%, and 95 %confidence level, respectively, compared to DMSO + Toxin control
conditions.
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post-intoxication conditions, the toxin was removed through
approved protocols, cell lysates were prepared, and the total
protein content was evaluated by Bradford assays. The degree
of SNAP-25 cleavage was determined using western blotting with
SNAP-25 antibodies (SMI-81, BioLegend). Briefly, samples were
subjected to the electrophoresis using 12% Tris-Glycine gels, and
the transfer for western blotting was conducted in wet conditions
using PVDFmembranes at 30 V for 2 h, using standard protocols.
The membranes were blocked in 5% skimmed milk dissolved in
0.01% TBS-T and then incubated in the primary antibody
solution overnight at 4°C. The membrane was washed two
times, re-blocked, and then incubated in secondary antibody
solution for 1 h at room temperature. The enhanced
chemiluminescence (ECL) substrate was used for visualization,
and the imaging and analyses were carried out using a SynGene
GeneGnome Chemiluminescence Imaging System.
MTT Assay
The human embryonic kidney cell line (HEK293) was cultured in
a growth medium consists of DMEM supplemented with 10%
Fetal Bovine Serum, 1% Glutamax, and 1% Penicillin-
Streptomycin, at 37°C with 5% CO2. HEK293 cells were plated
in 96-well culture plates and incubated for 24 h at 37°C, 5% CO2.
The cells were treated with the compounds at increasing
concentrations (1.25, 2.5, 5, 10, and 20 µM), and incubated for
4 h. Then, 3-(4,5-Dimethylthiazol-2-yl)−2,5 diphenyltetrazolium
bromide (MTT) solution was added to the cells, followed by the
addition of 1% SDS-0.01M HCl and the cells were incubated for
18 h. The absorbance measurement was conducted using a
microplate reader (Thermo Fisher Scientific) at 570 nm. The
readings were normalized to the blank controls and compared
to control conditions to calculate percent cell viability for each
condition.
Cycloheximide Chase Experiments
HEK293 cells were seeded in 24-well plates for 24 h and then
transfected with 1 µg plasmid encoding YFP-tagged A/LC (a kind
gift from Dr. Yien Che Tsai, NCI-Frederick, Frederick, MD,
United States), using TurboFect Transfection Reagent
according to the manufacturer’s instructions. Cycloheximide
(CHX) (25 μg/ml) (Sigma-Aldrich, C7698) was added to the
transfected cells to inhibit new protein synthesis 24 h post-
transfection. The time point that CHX added was collected as
“CHX 0 h control”. Cells were then incubated in CHX for 2 h in a
humidified incubator with 5% CO2 at 37°C. After 2 h, the media
containing the CHX was removed, and the indicated compounds
(20 µM) were applied to the cultures, which is designated as
“Compound Addition 0 h” time point. The cells were further
incubated and lysed at the specified time points indicated in
Figure 5 in NP-40 lysis buffer (5 M NaCl, 10% NP-40, 1 M Tris
pH 8.0), containing freshly added protease and phosphatase
inhibitors. Western blotting was utilized using GFP antibodies
(Invitrogen, A11122 and Santa Cruz Biotechnologies, sc-9996) to
determine A/LC degradation. Each western blot was stripped and
reprobed with β-Actin as the loading control, and the data
quantification (Figure 5B) was conducted by normalizing the
GFP levels to β-Actin of each individual blot.
Ubiquitination Assay
To determine the ubiquitination of BoNT/A LC, HEK293 cells
were co-transfected with HA-tagged Ubiquitin (a kind gift from
Dr. Lino Tessarollo, NCI-Frederick, Frederick, MD,
United States) and YFP-tagged A/LC using TurboFect
Transfection Reagent and cultured for 40 h. The cells were
treated with the compounds (20 µM) and harvested after
30 min and 3 h post-treatment, using ubiquitination lysis
buffer (30 mM Tris. HCl pH8, 75 mM NaCl, 10% Glycerol, 1%
Triton X-100, and freshly added protease inhibitor and
phosphatase inhibitor). Lysates were then processed and
precleared, followed by YFP-LCA immunoprecipitation with a
monoclonal GFP antibody (Santa Cruz Biotechnologies, sc-9996)
or a control IgG (normal mouse IgG, Santa Cruz Biotechnologies,
sc-2025), using protein G magnetic beads (SureBeads) (BioRad),
according to the manufacturer’s IP protocol. Following, samples
were subjected to western blotting, and ubiquitination levels were
determined using HA antibodies (Sigma, H6908), similar to
previous studies (Tsai et al., 2010; Tsai et al., 2017). Each
western blot was stripped and re-probed with GFP antibodies.
The data were quantified by normalizing the ubiquitination signal
to GFP levels on the same blot.
RESULTS
Screening of a Small Molecule UPP Inhibitor
Library for BoNT Holotoxin Inhibition in
Mouse ES-Derived Motor Neurons at
Pre-intoxication Conditions
To test the potential inhibitory effects of the small molecules
targeting UPP against BoNT/A, we examined the effects of each
compound in the library on BoNT/Amediated cleavage of SNAP-
25 in mouse ES-derived motor neurons. It is well established that
SNAP-25 is the only known biological target of BoNT/A, and the
toxin-mediated SNAP-25 protein cleavage is routinely used as a
read-out to measure the toxin’s biological activity in cells (Kiris
et al., 2014a). BoNT/A removes nine amino acids from the
C-terminal end of SNAP-25, and the resulting large fragment
can be separated from intact SNAP-25 via SDS-PAGE, and the
percentage of full-length (uncleaved) SNAP-25 is typically
calculated via western blotting as a measurement of toxin
activity (Kiris et al., 2011). Given that BoNT/A naturally
targets motor neurons, mouse ES-derived motor neurons serve
as physiologically relevant mammalian cell culture systems (Kiris
et al., 2014a). We conducted the initial screen at pre-intoxication
conditions in which mouse ES-derived motor neurons were
cultured in 24-well plates and treated with small molecules
(20 µM) for 30 min, and then the cells were intoxicated with
BoNT/A holotoxin (500 pM) for 4 hours. Our western blot
analyses demonstrated that WP1130, b-AP15, NSC-632839,
PR-619, P22077, Celastrol, MDBN, PYR-41, Serdemetan, NSC-
66811, and SL-01 statistically significantly protect SNAP-25
against BoNT/A holotoxin (Figure 1). Since two small
molecules (LDN-57444 and DbeQ) affect the SNAP-25 and/or
β-actin protein levels, they were excluded from further analyses.
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Neurons were morphologically examined in each experimental
condition with compounds, and Serdemetan was removed from
the pool of selected compounds because of its potential toxic
effects on neurons based on morphological analyses and
additional tests exhibiting inconsistent results. Toosendanin
treatment (1 µM) was used as a positive control group (Shi
and Wang, 2004), and as expected, it demonstrated complete
protection against the toxin. The most exciting part of these
results is that PR-619, known to affect VCIP135 (Tsai et al.,
2017), inhibited BoNT/A holotoxin mediated SNAP-25
cleavage (Figure 1). Another small molecule, WP-1130,
which affects USP9X, also exhibited inhibitory activity
against BoNT/A in neurons. Taken together, WP1130,
b-AP15, NSC632839, PR-619, P22077, Celastrol, MDBN,
PYR-41, NSC66811, and SL-01, were selected for further
studies based on our initial screen. 2D-structures of the lead
compounds are given in Figure 2.
Selected Compounds Exhibit
Dose-dependent Effects Against BoNT/A
Holotoxin in Neurons
Selected compounds were then evaluated for their potential dose-
dependent effects on the inhibition of BoNT/A mediated SNAP-
25 cleavage in pre-intoxication conditions, similar to Figure 1.
The ES-cell-derived motor neurons were treated with the
compounds at varying concentrations (1.25, 2.5, 5, 10, and
20 µM) 30 min before 500 pM BoNT/A holotoxin intoxication
of 4 hours. Similar to the initial screen, SNAP-25 cleavage was
utilized as a read-out, and the effectiveness of the compounds was
tested by determining the percentage of full-length SNAP-25 in
each experimental condition compared to DMSO control
conditions run with each compound set (Figure 3). SMER3,
which did not show significant protection in the initial screen
(Figure 1), was utilized as a negative control, which, as expected,
did not lead to dose-dependent protection against BoNT/A
holotoxin (Figure 3). Toosendanin treatment (1 µM) was used
as a positive control, which exhibited complete protection.
Excitingly, some of our lead compounds led to dose-
dependent protection against the BoNT/A challenge, and
20 µM was the most effective dose for the most efficacious
compounds to inhibit BoNT/A mediated SNAP-25 cleavage
(Figure 3). In particular, Celastrol exhibited statistically
significant protection at lower µM (as low as 2.5 µM)
concentrations. Similarly, WP1130 and PR-619 affected BoNT/
A mediated cleavage of SNAP-25 in a dose-dependent manner,
and the results were statistically significant at as low as 5 μM
b-AP15, NSC-632839, P22077, MDBN, and SL-01 also inhibited
BoNT/A mediated SNAP-25 proteolysis in a dose-dependent
manner but to a lesser extent. Inhibitory effects of PYR-41
and NSC66811 were only significant at 20 µM concentrations
(Figure 3). Taken together, these analyses demonstrated that
some of the lead compounds, including Celastrol, WP1130, and
PR-619, are efficacious against BoNT/A holotoxin in a dose-
dependent manner in pre-intoxication conditions.
The Effects of Selected Compounds on the
Cell Viability
We performed an MTT assay using HEK293 cells to determine
whether the compounds have any potential toxic effects on cells.
HEK293 cells are commonly utilized in viability measurements
upon compound treatments (Class et al., 2015). HEK293 cells
were treated with selected compounds at 1.25, 2.5, 5, 10, and
20 µM concentrations for 4 h, followed by MTT treatment and
incubation for 18 additional hours. The control group was treated
with DMSO as the compounds were dissolved in DMSO. We
have not detected statistically significant viability differences in
FIGURE 2 | 2D-Chemical structures of the lead compounds. WP-1130, b-AP15, NSC 632839, PR-619, P22077, Celastrol, MDBN, PYR-41, NSC 66811, and
SL-01.
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any of the compound-treated conditions compared to the control
conditions (Figure 4).
Selected Compounds Enhances the
Degradation of BoNT/A LC in Cells
To investigate the effects of selected compounds on the
degradation of the catalytic domain of BoNT/A, we sought to
measure the changes in the protein level of YFP tagged BoNT/A
LC at various time points after compound treatments. To do so,
we utilized cycloheximide (CHX), a protein synthesis inhibitor,
and performed chase experiments similar to previous studies
(Tsai et al., 2017). “CHX 0 h” indicates the time point when CHX
was added to HEK293 cultures after 24 h of post-transfection of
YFP tagged BoNT/A LC. After 2 h of CHX treatment, cells were
washed thoroughly, and selected compounds (20 µM) were
administered to the cultures. Then, the samples were collected
at various time points (0, 3, 6, and 9 h) to determine the effects of
compounds on BoNT/A LC protein levels in cells. Cycloheximide
is typically utilized at 50 μg/ml concentrations (Tsai et al., 2017;
Tsai et al., 2010); however, we utilized a lower concentration
(25 μg/ml) to achieve a relatively less A/LC degradation for easier
detection of the effects of the compounds. Figure 5A shows
representative YFP-LCA protein levels at indicated time points
detected by western blotting using an anti-GFP antibody for each
selected compound. DMSO treatment was utilized as a negative
control. Our data demonstrate that eight out of ten tested
compounds led to significant and time-dependent degradation of
BoNT/A LC in cells (Figures 5A,B). For example, PR-619,
WP1130, b-AP15, and Celastrol exhibited a highly significant effect
on the degradation of A/LC, especially at 6 and 9 h time points. This
finding is exciting as PR-619 and WP1130 inhibit VCIP135 and
USP9X, respectively, which regulate the half-life of A/LC (Tsai
et al., 2017), as mentioned above. NSC-632839, MBDN, PYR-41,
and SL-01 also demonstrated efficacy on A/LC degradation but to
a lesser extent. Interestingly, two compounds, P22077 and NSC66811,
did not result in significant degradation of BoNT/A LC, although they
inhibited the toxin in holotoxin experiments, suggesting that they may
FIGURE 3 | Dose-dependent effects of the selected compounds against BoNT/A holotoxin mediated SNAP-25 cleavage. Mouse ES-cell-derived motor neurons
were treated with the compounds at increasing doses (1.25, 2.5, 5, 10, and 20 µM) for 30 min before intoxication with 500 pM BoNT/A holotoxin. The total intoxication
time was 4 h. Toosendanin treatment (1 µM) was utilized as a positive control. β-III Tubulin was used as a loading control. Western blots are representatives of three
independent experiments, and the data are presented as means ± SEM.+++,++,+ Value significant at 99.9%, 99%, and 95 %confidence level, respectively,
compared to DMSO + Toxin control condition of each compound set.
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lead to inhibition through other unknown mechanisms than directly
affecting the ubiquitination of the A/LC. Taken together, some of the
lead compounds exhibited a highly significant effect on A/LC
degradation in cells.
Selected Compounds Promote the
Ubiquitination of BoNT/A LC in Cells
We then sought to determine the effects of selected compounds
on the BoNT/A LC ubiquitination in cells. BoNT/A LC
ubiquitination experiments were conducted similar to previous
studies (Tsai et al., 2010; Tsai et al., 2017). HEK293 cells
transfected with HA-Ubiquitin and YFP-tagged BoNT/A LC
plasmids were treated with the compounds (20 µM) at
indicated time points. We have not utilized CHX to inhibit
new protein synthesis in these experiments, so the cells were
only treated with the compounds in question. BoNT/A LC was
immunoprecipitated with GFP antibodies, and samples were
subjected to western blotting with HA antibodies to detect
ubiquitination, similar to previous studies (Tsai et al., 2010;
FIGURE 4 | The Effects of Selected Compounds on the Cell Viability. MTT assay was performed using HEK293 cells treated with selected compounds at 1.25, 2.5,
5, 10, and 20 µM concentrations. Data are presented as means ± SEM calculated from four independent experiments and compared by Student’s t-test, using
GraphPad Prism. “ns” stands for not significant.
FIGURE 5 | Selected Compounds Enhance the Degradation of BoNT/A LC in Cells (A) Representative western blot images demonstrating YFP-LCA protein levels
at the indicated time points. HEK293 cells were transfected with YFP-LCA and after 24 h incubated with CHX. After 2 h of incubation with CHX, media was removed, and
selected compounds (20 µM) were added to the cells and incubated for the indicated time points. “CHX 0 h” indicates the time point when CHXwas added. “Compound
treatment 0 h” indicates the time point when compound treatment was conducted. YFP-LCA expression levels were detected using an anti-GFP antibody. Each
western blot was stripped and reprobed with β-Actin as the loading control, and the figure includes a representative β-Actin. (B)Quantitative analysis of YFP-LCA protein
levels for each compound at the indicated time points. The data quantification was conducted by normalizing the GFP levels to β-Actin of each individual blot. Data are
presented as means ± SEM calculated from three independent experiments and compared to corresponding “CHX 0 h” control conditions of each set, using GraphPad
Prism (Student’s t-test). +++, ++, + Value significant at 99.9, 99, and 95% confidence level, respectively. “ns” stands for not significant.
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Tsai et al., 2017). Each individual western blot was stripped and
reprobed with GFP antibodies, and the data were quantified by
normalizing the ubiquitination signal to GFP levels on the same
blot. The DUB inhibitors WP1130 and PR-619 statistically
significantly enhanced A/LC ubiquitination in 30 min
compared to DMSO control conditions (Figures 6A,B), and
the ubiquitinated A/LC levels were decreased at 3 h time
points compared to 30 min time points, which may suggest
degradation of A/LC as observed in Figure 5, although the
decrease for PR-619 was not statistically significant
(Figure 6B). Celastrol led to statistically significant A/LC
ubiquitination at 30 min time point and a trend of gradual
accumulation at 3 h time point compared to 30 min. Similarly,
b-AP15 and NSC-66811 treatments resulted in enhanced and
accumulated A/LC ubiquitination, which was statistically
significant at 3 h time points for both. MDBN and PYR-41
also enhanced the ubiquitination of the A/LC, which was
statistically significant for both at 30 min time points, while
NSC-632839, P22077, and SL-01 did not exhibit a statistically
significant effect (Figures 6A,B).
FIGURE 6 | Selected Compounds Promote the Ubiquitination of BoNT/A LC in Cells. (A) HEK293 cells were co-transfected with HA-Ubiquitin and YFP-tagged
BoNT/A LC plasmids for 24 h, then treated with the compounds (20 µM), and samples were collected at the indicated time points. YFP-tagged BoNT/A LC was
immunoprecipitated with GFP antibodies or a normal mouse control IgG, and an HA antibody was utilized to detect ubiquitination. Each blot was stripped and re-probed
with GFP antibodies. (B) Quantitative analysis of YFP-LCA ubiquitination levels in each compound treated conditions as compared DMSO control condition at the
indicated time points. Data in each blot was normalized to corresponding GFP (YFP-A/LC) levels. Data are presented as means ± SEM calculated from three
independent experiments and compared by Student’s t-test, using GraphPad Prism. “ns” stands for not significant.
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WP1130, PR-619 and Celastrol Are Effective
Against BoNT/A Post-intoxication
BoNT/A is well known for its long-lasting effects in the cytosol,
and it is crucial to identify compounds that can inhibit BoNT/A
enzymatic activity in intoxicated neurons. To determine whether
selected UPP modulators can inhibit BoNT/A mediated SNAP-
25 cleavage in post-intoxication conditions, we first intoxicated
mouse ES-derived motor neurons with the indicated amounts of
BoNT/A holotoxin and then treated the cultures with the
compounds (20 µM) for 30 min after the intoxication started.
The compounds were tested against a higher BoNT/A holotoxin
challenge (1,000 pM) as opposed to 500 pM concentrations
utilized in Figures 1, 3. Our results demonstrated that three
compounds, WP1130, PR-619, and Celastrol, statistically
significantly inhibited BoNT/A mediated SNAP-25 cleavage
post-intoxication (Figure 7).
DISCUSSION
This work identified small molecule UPP inhibitors as novel
modulators of BoNT/A in cells. There is an urgent need for
therapeutic modalities to inhibit BoNT/A intoxication, especially
after the toxin enters the neurons, where it can exhibit its toxic
activity for up to 6 months (Lin et al., 2019). This is important
because BoNT/A formulations are extensively used in clinics
(Choudhury et al., 2021), and the wide distribution leads to
concerns regarding accidents. Also, BoNT/A intoxications can
naturally occur through food or liquid contaminations
(Thirunavukkarasu et al., 2018). In addition, there is a
potential for misuse of this relatively easy-to-produce toxin
(Arnon et al., 2001). Various classes of small molecules
inhibiting the toxin directly or through neuronal processes
that may be curial for intoxication and/or recovery have been
identified (Videnovic et al., 2014; Azarnia Tehran et al., 2015; Seki
et al., 2015; Bremer et al., 2017a; Bremer et al., 2017b;
Konstantinovic et al., 2018; Lin et al., 2019; Vazquez-Cintron
et al., 2020; Patel et al., 2021). However, none of those candidates
have yet progressed to FDA-approved drugs (Lin et al., 2019),
suggesting the need for novel approaches.
One potential approach to modulate BoNT/A intoxication in
cells would be targeting the persistence of A/LC (Kiris et al.,
2014b). Previous work employing designer E3 ligases or A/LC
specific single-chain antibodies fused to an F-box domain
demonstrated that it is possible to expedite A/LC degradation
in cells (Tsai et al., 2010; Kuo et al., 2011). Foreign proteins in
normal functioning cells can be labeled with ubiquitin molecules
for degradation by the UPP (Landré et al., 2014). However,
BoNT/A can remarkably escape from this system (Tsai et al.,
2017). Serotype A is the longest-lasting serotype in human
botulism; it can survive within the neurons for up to 6 months
(Shoemaker and Oyler, 2013). However, serotype E is active for
just a few days to weeks, although it targets the same protein,
SNAP-25, as BoNT/A (Shoemaker and Oyler, 2013). A recent
study shows that the E3 ubiquitin ligase TRAF2 mediated
ubiquitination destroys BoNT/E in neurons (Tsai et al., 2010).
BoNT/A is also efficiently ubiquitinated by the E3 ligase
HECTD2; however, the deubiquitinase VCIP135 removes the
ubiquitin and thereby stabilizes the toxin by preventing its
degradation (Tsai et al., 2017). Therefore, HECTD2 and
VCIP135 activities appear to be essential for determining the
lifetime of BoNT/A and the duration of its action in neurons. It is
also important to mention that VCIP135 may not be the only
DUB affecting A/LC half-life as it is shown that there is another
DUB, USP9X, whichmight have an indirect effect on BoNT/A LC
degradation (Tsai et al., 2017). The half-life of BoNT/A in cells
can be potentially controlled if the E3 ligase and/or the DUBs can
be manipulated.
Ubiquitination is a crucial post-translational process
controlling many functions in cells, including protein
turnover, localization, and endocytosis (Oh et al., 2018).
Importantly, this is a reversible process, and DUBs can
remove ubiquitin chains from the substrates (Clague et al.,
2019). Many components in the UPP pathway have been
targeted for drug development for various diseases, including
cancer and neurodegenerative conditions. Such efforts led to the
development of FDA-approved UPP targeting therapeutics. For
example, proteasome inhibitors Bortezomib, Carfilzomib,
Ixazomib, and E3 modulators Thalidomide, Lenalidomide, and
Pomalidomide are FDA approved while there are many UPP
targeting molecules, including DUBmodulators, that are either in
clinical trials and or in preclinical stages (Wu et al., 2020).
FIGURE 7 |WP1130, PR-619, and Celastrol are effective against BoNT/
A post-intoxication. Mouse ES cell-derived motor neurons were exposed to
BoNT/A holotoxin at indicated concentrations for 30 min and then treated with
20 µM of the selected UPPmodulators. After 4 h of total intoxication, cell
lysates were prepared and subjected to western blotting to determine the
degree of SNAP-25 cleavage. The blots were stripped and re-probed with
β-Actin antibodies as the loading control. The values are given as mean ± SEM
from three independent experiments. Statistical significance was calculated
for each compound treatment as compared to DMSO + toxin only (1,000pM
BoNT/A) control condition run on the same blot, using GraphPad Prism
(Student’s t-test). +++, ++ Value significant at 99.9 and 99% confidence
level, respectively.
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Although proteasome and E1 targeting small molecules may lead
to cellular toxicity due to non-specific effects, recent work has
focused on developing specific E3 ligase and DUB modulators,
and it has been shown that selective DUB inhibitor development
is possible (Harrigan et al., 2018). DUBs are attractive drug targets
due to their diversity and well-defined catalytic clefts (Clague
et al., 2019; Basar et al., 2021), and indeed selective deubiquitinase
inhibitors have been identified (Clancy et al., 2021; Varca et al.,
2021).
Among the identified BoNT inhibitors in this study, PR-619
andWP1130 are of high interest as these are both DUB inhibitors
with targets relevant to BoNT/A LC modulation. PR-619 is
known to inhibit VCIP135 (Altun et al., 2011), which is
previously identified as the main DUB inhibiting the
degradation of BoNT/A LC (Tsai et al., 2017). PR-619 is a
cell-permeable and reversible DUB inhibitor (Altun et al.,
2011; Tian et al., 2011). It has been shown that PR-619 can
enhance the ubiquitination of specific proteins, such as Bcl-2, and
thereby enhance its degradation (Kuo et al., 2019), which is
consistent with our findings (Figures 5, 6). WP1130, also
known as degrasyn, is also a cell-permeable, reversible, small
molecule that is considered the best described USP9X inhibitor
(Harrigan et al., 2018). It has been shown that WP1130 can lead
to enhanced ubiquitination and proteasome-dependent
degradation of USP9X target proteins (Wang et al., 2014;
Yang et al., 2016), which is consistent with our findings. It is,
however, important to note that both PR-619 and WP1130 are
not specific to the indicated targets. For example, WP1130 is
considered a partially selective USP9X inhibitor, as it also targets
other DUBs, USP14, USP5, and UCH37 (Kapuria et al., 2010).
Similarly, PR-619 is characterized as a broad-spectrum DUB
inhibitor (Altun et al., 2011). Therefore, further work is
needed to determine whether other molecular players
modulated by these compounds might play a role in the
observed inhibition of the A/LC-mediated SNAP-25 cleavage.
Importantly, there have been efforts to develop more potent and
selective inhibitors than PR-619 and WP1130 targeting the same
DUBs. For example, recently, a highly selective USP9X inhibitor,
FT709, as compared to WP1130, was developed and
characterized (Clancy et al., 2021). Future work evaluating
more selective DUB inhibitors may pave the road for drug
development against BoNT/A intoxication.
Another important finding of this study was identifying
Celastrol as a regulator of A/LC ubiquitination and
degradation (Figures 5, 6), which demonstrated efficacy
against BoNT/A holotoxin mediated SNAP-25 cleavage in
both pre-and post-intoxication conditions (Figures 1, 3, 7).
Celastrol is a natural product derived from Tripterygium
wilfordii, with anti-inflammatory and antioxidant activities
(Venkatesha et al., 2016). Importantly, celastrol is
pharmacologically active, and it can cross the blood-brain
barrier, making it the focus of many studies in the context of
many human diseases, including central nervous system
disorders (Bai et al., 2021). Celastrol has multiple targets in
cells (Chen et al., 2018), and its treatment has been shown to
lead to degradation of specific proteins via the ubiquitin-
proteasome pathway, including FANCD2 and mTOR
(Metselaar et al., 2019; Wang et al., 2015; Li et al., 2018),
which is in line with our results demonstrating the
degradation of BoNT/A LC (Figure 5). Interestingly, Celastrol
led to significant degradation of BoNT/A LC; however, although
not statistically significant, we have observed an accumulation of
ubiquitinated A/LC (Figure 6). It has been demonstrated that
Celastrol is also a proteasome inhibitor, and therefore, it may be
possible that the degree of A/LC degradation is determined by the
balance between celastrol-mediated proteasome inhibition and
celastrol-mediated increase in A/LC ubiquitination. A similar
mechanism has been previously proposed for celastrol-mediated
mTOR ubiquitination and degradation (Li et al., 2018).
Our results showed that b-AP15, NSC632839, MDBN, PYR-
41, and SL-01, which do not target USP9X or VCIP135, exhibit
significant effects on the degradation of BoNT/A LC at varying
degrees (Figure 5). These results may be crucial because other
possible mechanisms might be important for the stability of
BoNT/A LC, different than VCIP135 and USP9X.
Alternatively, these compounds might indirectly affect USP9X
or VCIP135, leading to A/LC degradation. Notably, there has
been significant research on these compounds, which may help
future studies to better understand the roles of the compounds in
A/LC degradation. b-AP15 targets DUBs USP14 and UCHL5 in
19S proteasome (Tian et al., 2014; Fukui et al., 2019), resulting in
polyubiquitination accumulation (D’Arcy et al., 2011). However,
this appears to be context-dependent as it has been shown that
b-AP15 treatment can enhance poly-ubiquitination of Smad2 and
Smad3 and enhance their degradation in the lysosome (Nan et al.,
2016), which is consistent with our findings demonstrating that
b-AP15 leads to A/LC degradation and enhances its ubiquitination
in a time-dependent manner. NSC-632839 targets DUBs USP2 and
USP7 and deSUMOylase SENP2 (Nicholson et al., 2008), but is also
reported to induce caspase activation and apoptosis (Aleo et al.,
2006). In our analyses, NSC-632839 led to increased degradation of
A/LC (Figure 5); however, its effect on A/LC ubiquitination was not
significant despite there was a trend of increased A/LC
ubiquitination (Figure 6). P22077 is also a DUB inhibitor
targeting mainly USP7 and USP47 (Altun et al., 2011).
Interestingly, this compound did not exhibit a significant effect
on A/LC degradation (Figure 5) and ubiquitination (Figure 6) even
though it antagonized BoNT/A holotoxin mediated SNAP-25
cleavage in pre-intoxication conditions, suggesting that the
compound might affect other mechanisms, such as entry steps,
etc. in the intoxication mechanisms. MDBN is a cell-permeable,
irreversible inhibitor of p97/valosin-containing protein that has been
shown to promote ubiquitination in cells (Schweitzer et al., 2016),
which is in line with our findings. PYR-41 is a cell-permeable E1
ligase inhibitor (Yang et al., 2007); however, it also targets several
DUBs and some kinases (Kapuria et al., 2011). NSC-66811 and SL-
01 both target E3 ubiquitin-protein ligase Mdm2 (Lu et al., 2006; Li
et al., 2011). Taken together, these compounds and their potential
targets within the context of BoNT/A LC stability should be further
investigated in future studies. Such further characterizations should
include analyses to determine whether the lead compounds might
directly inhibit the enzymatic activity of A/LC, which is a zinc-
dependent endopeptidase (Lebeda et al., 2010). Our analyses
demonstrated that the lead compounds did not exhibit a
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significant effect on cell viability at tested concentrations (1.25, 2.5, 5,
10, and 20 µM), based on theMTT assay (Figure 4). Considering the
experimental conditions and the exposure time of compounds in
culture, in which they exhibited apparent activity against the toxin, in
the initial screen (Figure 1), dose-response (Figure 3), and post-
intoxication (Figure 7) analyses, we exposed the cells to compounds
for 4 h in our MTT assay. However, future characterizations of the
lead compounds should also include further toxicological testings
with various compound treatment time points.
An effective strategy to treat botulism patients may involve a
combination therapy in which specific immunoglobulins can be
used to neutralize the toxin before cellular entry, coupled with drugs
that can inhibit the biological activity of the already internalized
toxin. Indeed, there are approved anti-BoNT antibody therapies,
which are effective before BoNTs gain access into the cells (Rasetti-
Escargueil and Popoff, 2019). However, as indicated above, there are
currently no approved drugs against the already internalized active
toxin (Lin et al., 2019). Only a limited number of BoNTmolecules in
cells can be sufficient to block neurotransmission (Hanig and
Lamanna, 1979), and multiple groups have demonstrated that
cleavage of a relatively small fraction of total SNAP-25 by A/LC
is sufficient to cause significant inhibition of neuroexocytosis (Keller
and Neale, 2001; Meunier et al., 2003; Keller et al., 2004; Beske et al.,
2015). Given that A/LC can survive in cells for months (Shoemaker
and Oyler, 2013), it would be ideal to eliminate already internalized
A/LC to complement approved antibody therapies. Our work in this
study focused solely on BoNT/A; however, it is crucial to develop
inhibitors that can be effective against multiple BoNT serotypes. It
has been shown that BoNT/E is degraded relatively rapidly
compared to BoNT/A due to ubiquitination by a different E3
ligase than that of BoNT/A (Tsai et al., 2010). Future work
should evaluate whether the ubiquitin-proteasome pathway can
also be modulated to target serotype E and potentially other
serotypes.
In summary, this study identified a subset of UPP targeting
small molecules that inhibits BoNT/A LC activity in cells; two of
the most efficacious compounds are DUB inhibitors. This is
important as DUBs are considered druggable targets with
significant clinical potential for various conditions (Magin
et al., 2021). Initial studies described herein provide proof-of-
concept data indicating that small molecules targeting UPP can
be useful for attenuating BoNT/A intoxication. Modulating
BoNT half-life in cells by small molecules can be important
for research purposes to understand intoxication/recovery
mechanisms and the development of effective countermeasures
against botulism.
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